Durable Disease Control with Obexelimab in IgG4-Related Disease: Phase 3 INDIGO Open-Label Extension (ACR Convergence 2026) - Oct 16, 2026 - Abstract #LB18; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; "These OLE findings demonstrate sustained clinical activity of obexelimab, with low flare rates and limited GC rescue during continued treatment. The safety profile remained consistent with the RCP, with no new safety signals identified. Together, these findings support the potential for long-term disease control with continued obexelimab treatment in IgG4-RD."
Clinical • Late-breaking abstract • P3 data • Infectious Disease • Inflammation • Musculoskeletal Pain • Pruritus • Respiratory Diseases
|
|
John Stone 1; Matthew Baker 2; Emanuel Della Torre 3; Wen Zhang 4; Guy Katz 5; Luke Chen 6; Mollie Carruthers 7; Thomas J. Greene 8; Admasu Mamuye 9; Audrey Wells 10; and Emma Culver 11
|